Yet another drug company admission.
http://www.nytimes.com/2004/10/16/business/16pfizer.html?hp&ex=1097985600&en=edf084e6796bf4bc&ei=5094&partner=homepagePfizer warned doctors yesterday that one of its best-selling painkillers, Bextra, might increase the risk of heart attack or stroke in coronary artery bypass surgery patients. The announcement comes just two weeks after Merck removed from the market its painkiller, Vioxx, which is in the same class of medicines as Bextra, because a study showed that the risk of heart attacks doubled for patients who had taken Vioxx 18 months or longer.
Pfizer said a clinical study involving more than 1,500 patients showed that those who had undergone bypass surgery and had taken Bextra intravenously and orally were at higher risk for heart attacks. An initial study last year raised similar concerns in the same kinds of patients.
The painkillers known as COX-2 inhibitors, which include Bextra and Vioxx, have been widely prescribed to people with arthritis. Merck's decision to withdraw Vioxx cast suspicion on the safety of drugs in that class. Now Pfizer's warning is sure to fuel the debate about the overall safety of these drugs for all patients.
<more>